Related Experiment Video
Updated: Dec 25, 2025
05:16
Sleeve Gastrectomy in Mice using Surgical Clips
Published on: November 14, 2020
7.2K
Insulin resistance in bariatric surgery
Erik Stenberg1, Anders Thorell2,3
1Faculty of Medicine and Health, Örebro University & Department of Surgery, Region Örebro County, Örebro, Sweden.
Current Opinion in Clinical Nutrition and Metabolic Care
|March 25, 2020
Summary
Bariatric surgery significantly improves glucose control in obese patients by altering nutrient absorption and reducing adipose tissue. This leads to diabetes remission and prevention of related complications.
Area of Science:
- Metabolic Surgery
- Endocrinology
- Obesity Medicine
Background:
- Bariatric surgery is a highly effective treatment for obesity and associated metabolic disorders.
- Mechanisms include calorie restriction, nutrient diversion, and adipose tissue reduction.
- Improved glucose control and reduced diabetes complications are key clinical outcomes.
Purpose of the Study:
- To review the mechanisms and clinical effects of improved glucose control after bariatric surgery.
- To update on recent findings regarding metabolic adaptations.
- To highlight the role of bariatric surgery in managing obesity and type 2 diabetes.
Main Methods:
- Literature review of studies on bariatric surgery.
- Analysis of physiological and hormonal changes post-surgery.
- Evaluation of clinical outcomes, including diabetes remission and complication rates.
Main Results:
- Early nutrient diversion impacts gut hormone release and microbiota.
- Long-term adipose tissue loss improves insulin sensitivity and reduces inflammation.
- Clinical benefits include diabetes remission, prevention, and reduced micro/macrovascular complications.
Conclusions:
- Bariatric surgery is the most effective treatment for improving glucose control in obesity.
- Understanding the complex mechanisms can lead to better treatment strategies.
- Further research is needed to fully elucidate the metabolic effects.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
581
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
581
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
187
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
187
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
531
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
531
01:36Carbohydrate Metabolism
13.6K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
13.6K
01:24Glucagon-like Receptor Agonists
757
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
757
01:28Insulin: The Receptor and Signaling Pathways
2.4K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.4K